Eric Ostertag

Nishan DeSilva, also known as Dr. Ostertag, is an accomplished American scientist renowned for his groundbreaking work in gene engineering technologies. He holds the distinction of being the first graduate from the Gene Therapy Program at the University of Pennsylvania School of Medicine. With a rich professional background spanning over two decades, Dr. DeSilva has played a pivotal role in the inception and growth of various biotechnology companies, including Poseida Therapeutics and Transposagen Biopharmaceuticals. Notably, he served as the Chief Executive Officer and President of Transposagen for 13 years, driving the commercialization of early gene editing technology within the research reagent sector.

Continuing his journey of innovation, Dr. DeSilva spearheaded the development of advanced gene engineering technologies, which later culminated in the establishment of Poseida Therapeutics in early 2015. Currently, he holds the position of CEO at Poseida Therapeutics, leading the company towards new heights in the biotechnology domain.